Fontan-Associated and Other Vascular Liver Diseases: Hepatocellular Carcinoma Risk, Surveillance, and Diagnosis

Nov 09 2025
Convention Center: Ballroom C, Level 3
2:00 PM - 3:30 PM

World Class Speakers

Takeshi Yokoo, MD PhD
Presenter

Takeshi Yokoo, MD PhD

University of Texas Southwestern
David E Kaplan, MD, MS, MSc, FAASLD, FACP, AGAF
Presenter

David E Kaplan, MD, MS, MSc, FAASLD, FACP, AGAF

University of Pennsylvania
Moira B Hilscher
Moderator

Moira B Hilscher

Penn Medicine

Description

HCC and other liver nodules can develop in patients with Fontan-associated liver disease (FALD) and other vascular liver diseases, which may include conditions such as heart failure and Budd-Chiari syndrome. Currently, the Liver Imaging Reporting and Data System (LI-RADS)—a widely used tool for the imaging diagnosis of HCC—cannot be applied to these patients due to insufficient data and the low specificity of imaging in this context. This session provides an overview of cardiac/vascular liver disease and associated HCC risk. Speakers discuss the controversial topic of HCC surveillance in patients without cirrhosis, explore appropriate surveillance strategies for high-risk patients including those with cirrhosis, and address the diagnostic challenges faced by this population.

 

Journey Maps

Presentations

2:15 PM - 2:30 PM
Nov 09 2025
San Diego, CA

Non-Fontan Vascular Liver Disease and Hepatocellular Carcinoma Risk

David E Kaplan, MD, MS, MSc, FAASLD, FACP, AGAF, Presenter
Liver Cancer
2:30 PM - 2:45 PM
Nov 09 2025
San Diego, CA

Hepatocellular Carcinoma: Surveillance Modalities and Patient Populations for Whom Surveillance Is Indicated

Yuko Kono, MD, PhD, FAASLD, Presenter
Liver Cancer
2:45 PM - 3:00 PM
Nov 09 2025
San Diego, CA

Diagnostic Challenges in Vascular Liver Disease: Modalities and When to Biopsy

Takeshi Yokoo, MD PhD, Presenter
Liver Cancer

Objectives

  • Review cardiac liver disease including Fontan-associated liver disease (FALD) and other vascular liver diseases and HCC risk in this population.
  • Discuss the challenges in HCC surveillance in cardiac and vascular liver disease, including how to risk stratify high-risk patients for HCC surveillance and the selection of optimal surveillance tests.
  • Describe how to diagnose benign liver nodules and HCC in cardiac and vascular liver diseases.
Chair

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Stanford University Medical Center
Chair

Yuko Kono, MD, PhD, FAASLD

University of California San Diego